“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Cantargia
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing antibodies against target IL1RAP to treat cancer and autoimmune diseases. Lead antibody CAN04 is currently being studied in a Phase I/II study in solid tumours focusing on NSCLC and pancreatic cancer. In this video, the company’s chief executive officer Göran Forsberg introduces the company and its lead asset, and provides an overview of R&D progress and expected newsflow.
Get access to the very latest content matched to your personal investment style.
